AVTX
Avalo Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$370.77M
P/E Ratio
—
EPS
$-5.84
Beta
0.94
52W High
$20.72
52W Low
$3.39
50-Day MA
$15.54
200-Day MA
$13.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Avalo Therapeutics Inc
Avalo Therapeutics Inc is a pioneering clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved conditions, particularly in the realm of immunological regulation. With a robust pipeline of proprietary candidates targeting serious diseases with significant unmet medical needs, Avalo leverages its deep expertise in disease mechanisms to advance its therapeutic programs through rigorous clinical trials. The company's dedication to scientific innovation and a patient-centric approach positions it to navigate the complexities of the biopharmaceutical industry effectively, with the goal of delivering transformative therapies to improve patient outcomes.
Fundamentals
| Revenue (TTM) | 59,000 |
| Gross Profit (TTM) | $-35.29M |
| EBITDA | $-72.58M |
| Operating Margin | -33461.00% |
| Return on Equity | -72.40% |
| Return on Assets | -34.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.49 |
| Price-to-Book | 4.86 |
| Price-to-Sales (TTM) | 6284.21 |
| EV/Revenue | 5184.19 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -69.30% |
| Shares Outstanding | $22.79M |
| Float | $17.25M |
| % Insiders | 2.77% |
| % Institutions | 97.89% |
Analyst Ratings
Consensus ($37.89 target)
1
Strong Buy10
BuyData last updated: 4/7/2026